(A) TGs in Ucp2+/+ or Ucp2–/– BMDMs treated with LPS (500 ng/ml) for 4 hours. *P < 0.05, ANOVA. (B) 18F-FDG uptake and PEP and lactate production in Ucp2+/+ or Ucp2–/– BMDMs treated with LPS (500 ng/ml) for 4 hours. *P < 0.05, ANOVA. (C) Citrate production in Ucp2+/+ or Ucp2–/– BMDMs treated with LPS (500 ng/ml) for 4 hours. *P < 0.05, ANOVA. (D) Immunoblot analysis for FASN, ACACA, and ACLY in cell lysates from Ucp2+/+ or Ucp2–/– BMDMs treated with LPS (500 ng/ml) for 4 hours. β-Actin served as the standard.